Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
ELCC 2025 – BioNTech impresses in small-cell lung
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
A fourth challenger from DualityBio and BioNTech
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
BioNTech puts a ring on Biotheus
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Next for Trodelvy: small-cell lung cancer
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
